Measles in Developing Countries by Onoja, Anyebe & Ajagbe, Oluwaseyi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Measles in Developing Countries
Anyebe Onoja and Oluwaseyi Ajagbe
Abstract
Measles is a major childhood problem which causes significant illness, death 
and disability. It infects approximately 40 million people resulting in nearly 1 
million deaths annually in developing countries. Measles virus accounts for 44% 
of total deaths among children that are less than 15 years of age. Highest mortal-
ity occurs among children living in poor communities especially in areas that are 
overcrowded, and where there is malnutrition and vaccination coverage is low. Most 
of the measles infections in the world are recorded in developing countries of Africa 
and Asia. Endemic areas are largely confined to the tropics, where transmission 
increases after rainy season. Inability to effectively immunize most children in this 
area has hampered global measles mortality reduction initiatives and reduction 
of under-five child mortality. Although, this was initially scheduled to have been 
met by 2015, recent WHO resolution called for measles elimination in the African 
Region by 2020. It is not certain that this will be met; hence the need for coordi-
nated and strategic mass vaccination efforts to target unimmunized children in 
these regions.
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1. Introduction
Measles is a serious medical problem in Africa, Latin America, Europe, south-
east Asia and eastern Mediterranean [1]. During the pre-vaccine era, 130 million 
measles cases occurred annually worldwide, and it was the leading cause of 
childhood deaths [2]. In Africa, about 13 million cases and 650,000 deaths occur 
annually, with sub-Saharan Africa having the highest morbidity and mortality [3]. 
In 2018, many developing countries reportedly confirmed measles through labora-
tory testing with high incidence rates. In AFRO region, Liberia confirmed 218 cases 
with 412.24% incidence rate. Similarly, Libya confirmed 286 cases with 98.84% 
incidence rate, Burkina Fasso confirmed 567 cases with 84.2% incidence rate and 
the southern part of the continent was not left out as Uganda confirmed 531 cases 
in the laboratory with incidence rate of 65.83%. In the Western Pacific region, 
Philippines confirmed 1677 cases with incidence rate of 118.5% while Malaysia 
confirmed 1374 cases with incidence rate of 80.35% [4]. In EURO region, Albania 
confirmed 1290 cases with incidence rate of 477.05%, Georgia reported 1091 
laboratory confirmed cases with 374.74% incidence rate and Kyrgyzstan confirmed 
376 cases in the laboratory with 75.22% incidence rate. In EMRO, Afghanistan 
reported 1846 laboratory confirmed cases with 62.64% incidence rate, Saudi 
Arabia reported 833 laboratory confirmed cases with 29.99% and 793 laboratory 
confirmed cases in Yemen with incidence rate of 344.36%. Venezuela in AMRO 
confirmed 5525 cases in the laboratory with an incidence rate of 23.03% [4].
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Despite the comprehensive WHO and United Nations International Children 
Emergency Fund’s (UNICEF’s) measles-reduction strategy, and partnership of 
international organizations for measles mortality reduction, certain countries con-
tinue to face recurrent epidemics [5]. The optimal age for infantile measles vaccina-
tion is an important since maternal antibodies may neutralize the vaccine antigen 
before specific immune response develops. Delaying vaccination on the other hand 
may increase risk of complicated disease [6]. Measles vaccine effectiveness is 84% 
when administered at 9–11 months of age and 93% when given at ≥12 months of 
age [7]. First dose of measles-containing vaccine (MCV1) given at 9 months of age 
was introduced into the Expanded Programme on Immunization (EPI) in 1977 [8]. 
Since >93–95% population immunity is required to prevent measles epidemics, the 
WHO recommends all children receive two doses of measles vaccine [9]. In Nigeria 
just like in many developing countries, children are given monovalent measles vac-
cine at 9 months of age in the EPI [10]. In 2010 and continuing through 2014, DRC 
experienced the largest nationwide measles outbreak in Africa [11–13]. DRC is a 
key country for regional elimination efforts because of its large population, central 
location with nine international borders, and persistent reservoir of circulating 
measles viruses [14]. The Reaching Every District (RED) approach to strengthening 
immunization services has been implemented beginning in some developing coun-
tries like Democratic Republic of Congo (DRC). A second opportunity for measles 
vaccination, nationwide measles supplementary immunization activities (SIAs) 
using a phased approach intended to cover the country every 3 years [15].
2. Epidemiology and immunization
2.1 Measles virus detection strategies and sero-surveillance in Africa
Following a successful polio laboratory platform, The Global Measles and 
Rubella Laboratory Network (GMRLN) was developed. As at 2018, there are 
presently 723 laboratories established in 164 countries. It was proposed that in all 
districts in WHO AFRO surveillance performance should target ≥2 cases of non-
measles febrile rash illness per 100,000 population and ≥1 suspected measles case 
investigated with blood specimens in ≥80% of districts [16]. Case-based surveil-
lance with laboratory confirmation of suspected measles cases is in place in many 
developing countries. Integrated Disease Surveillance and Response (IDSR) was 
established for aggregate reporting of 18 infectious diseases, including measles. 
Through the IDSR, aggregate numbers of suspected measles cases and deaths are 
reported weekly from districts to national level. Through measles case-based sur-
veillance, suspected measles cases were investigated using case investigation form 
and laboratory testing of blood specimen. Specimens are tested using standard 
enzyme-linked immunosorbent assays for measles-specific immunoglobulin M 
(IgM) antibodies. Suspected measles case was defined as an illness with maculopap-
ular rash and fever and one or more symptoms of cough, coryza or conjunctivitis, or 
where clinician suspects measles. Laboratory-confirmed measles case on the other 
hand is defined as suspected measles case with positive laboratory test result for 
measles specific IgM in the absence of measles vaccination within 30 days of speci-
men collection. An epidemiologically-linked case is suspected measles case having 
contact (or living in same district) with laboratory-confirmed measles case whose 
rash onset was within preceding 30 days. Clinically-compatible case is suspected 
measles case without laboratory test result or established epidemiological link. PCR 
detection is carried out in specific laboratories with technology for confirm hemag-
glutinin (H) and nucleoprotein (NP) gene of measles virus.
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2.2 Circulating genotypes and clades in Africa
Measles virus is monotypic; however, genetic variations occur in the H and NP 
genes. Currently, the WHO recognizes 8 clades, A-H which consists of 24 genotypes 
and an additional provisional genotype, D11. Clades B, C, D, G and H each contain 
multiple genotypes (B1-3, C1-2, D1-10, G1-3 and H1-2) while clades A, E and F each 
contain single genotype (A, E and F) respectively [17, 18]. Epidemiological findings 
reveal circulation of several genotypes in Africa. Genotype A has been detected 
in South America, parts of China and South Africa over the last 40 years [19], 
and recently in a 3 year old child in Nigeria West Africa [20]. The most endemic 
genotype circulating in Africa is B3. Studies have shown clade B to be endemic in 
sub-Saharan Africa [21] with B3 genotype reported in Ghana, Gambia, Nigeria, 
Libya and Tunisia [20, 22, 23]. The measles viruses isolated in 1983 from Yaoundé, 
Cameroon, were designated as B1 genotype. However, in 2001 viruses belonging 
to B3 genotype were found in the country. B3 genotype has been reported in the 
Gambia. The B3 genotype (2001) in Cameroon were related to B3.1 subgroup, 
whereas the Gambian (1993) isolates corresponded to B3.2 subgroup. Geographical 
distribution for period 1993–2001 of these two viruses shows that B3.1 is found 
from Sudan to Nigeria and Ghana extending to Cameroon, whereas B3.2 genotype 
is found in West Africa. In Nigeria and Ghana, the viruses co-circulate [3, 14]. 
Nucleotide sequence analysis show strains from Senegal clustered in B3.1 and B3.3 
sub-genotypes. Measles virus detected in Tunisia and Libya from 2002 to 2009 
belonged to genotype B3. Viruses isolated from 2002 to 2007 and 2009 were subtype 
B3.1. Seven of isolates during 2008 and 2009 epidemic were divergent from the B3 
isolates and can represent a new subtype of genotype B3 [21]. B3 strain circulates in 
Addis Ababa, Bahir Dar and possibly elsewhere in Ethiopia [24]. In a 2014 outbreak 
among refugees from Central African Republic in Cameroon, the genotype B3 
found were similar to those circulating in Northern Cameroon in 2010–2011 [25]. 
Clade B viruses is reported to be endemic in central and western parts of sub-Saha-
ran Africa while genotypes D2 and D4 has been continually detected in southern 
and eastern parts of Africa. D10 in Uganda is represented by Clade MVi/Kampala.
UGA/51.00.1 with accession number AY923185.1. Genotype C2 is found to circulate 
widely in northern Africa [17, 26–28].
2.3 MV complications in developing countries
Measles is characterized by fever of 38°C or more; maculopapular rash of 3 days 
or more; with one or combination of coryza, cough, conjunctivitis and Koplik spots 
in the oral mucosa of measles’ victims [29]. Mortality rates can exceed 10% in parts 
of the developing world. Sequela of measles includes giant cell pneumonia, inclu-
sion body encephalitis and sub-acute sclerosing pan encephalitis [SSPE] [30]. A 
study carried out in the largest children’s hospital in Ibadan-Nigeria in West Africa 
observed several complications ranging from bronchopneumonia (60%), heart 
failure (12%), gastroenteritis (11%), protein losing malnutrition (8%), encephalitis 
(5%), croup (2%) and dehydration (2%) [10], whereas bacterial complication is the 
usual cause of death when measles kills malnourished children [31].
2.4 Vaccination and herd immunity
After routine and catch-up vaccinations in 2005 and 2006, as well as follow-up 
vaccination by 2008 in Nigeria, remarkable level of protection was observed in 
children. This is attributed to immunological dynamics which is an after-effect of 
these campaigns [32]. Herd immunity varies between heterogeneous populations in 
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developing countries. Nigeria is the most populous country in Africa with a popula-
tion of over 160million. In an assessment of immune status carried out in 2014, herd 
immunity against measles was 66.8% in Kano State and 73.0% in Ibadan, Oyo State. 
These are two largely different populations in the north and southern respectively 
[33]. When history of measles was compared with level of immunity, a significant 
association was observed between those who had measles and who had protective 
immunity. There was strong correlation between malnutrition and immune level, a 
lot of malnourished children who were vaccinated were not protected [33].
2.5 Measles vaccination coverage in Africa
Strategies based on vaccination program have been implemented in order to 
reduce measles mortality. In 2008, countries in the WHO African Region adopted 
measles pre-elimination goal to be achieved by the end of 2012. Target was to 
achieve >98% reduction in estimated regional measles mortality. The goal was to 
have national measles incidence of <5 cases per 1,000,000 population per year, 
achieve >90% national coverage with MCV1 with >80% MCV1 coverage target. For 
SIAs, MCV coverage >95% was targeted in all districts [16]. In the WHO regions, 
highest percentage of reduction was in Eastern Mediterranean (90%) and African 
(89%) regions, accounting for 16 and 63% of global reduction [34, 35]. Relatively 
high measles vaccination in southern Nigeria in West Africa can be attributed to 
high level of literacy and awareness created by free use of mass media to dissemi-
nate information on vaccination activities, without fear of intimidation [33]. The 
Global Vaccine Action Plan (GVAP) set out a target of reaching 80% coverage with 
all vaccines including measles vaccine in all districts by 2020 [36]. Health policy 
decision-making based on spatially heterogeneous vaccination has resulted in shift 
from pursuing coverage targets at national-level to ensuring high coverage levels 
evenly distributed across provinces or districts [37]. While this likely represents a 
more effective strategy over targeting country-level goals, administrative area sum-
maries may still mask important geographical inequities in coverage [38].
2.6 Challenges of measles immunization in resource-limited settings
Vaccination history of children is not documented in hospital’s records because 
many people do not properly keep children’s/wards’ vaccination records. This is 
coupled with high illiteracy level found in many developing countries [32]. Many 
people present as emergencies upon admission, at which point their parents cared 
less about vaccination status because they were overwhelmed by anxiety. There is 
need for enhanced comprehensive national vaccination campaigns with intense com-
munity engagement and diligent health workers including large number of ad-hoc 
staff. Weak government support across all levels is responsible for poor surveillance 
activities hence, their inability to detect new cases. Awareness creation should be 
intensified to inform concerned citizens about the essence and time of vaccination.
Ability to produce vaccines is a major setback for developing countries. Japan 
International Cooperation Agency (JICA) is currently supporting transfer of a 
Measles-Rubella vaccine manufacturing technology to Polyvac® in Vietnam, 
following the precedent set by multiple previous successful projects. Transfer 
of an oral polio vaccine (OPV) technology from Biken Co., Ltd. to Bio Farma 
in Indonesia was pivotal in the global polio eradication efforts. JICA supports 
UNICEF supply of vaccine cold chain equipment to India, Afghanistan, Angola, 
Liberia, Zambia and Zimbabwe which has significantly overcome the problem of 
vaccine failure resulting from inability of most immunization officers to maintain 
cold chain in remote areas.
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Government bodies responsible for ensuring safety and effectiveness of vaccines 
face serious challenges when protecting the public from harm once the products are 
used in uncontrolled, real world context [39–41]. Regulations have been moving 
towards an approach that takes into account the full lifecycle of the vaccine. While 
this shift has been very slow in countries like Canada, there have been further 
calls for changes on how regulators safeguard public health and public healthcare 
resources [42]. This approaches are a far cry from the reality on ground in develop-
ing countries, because they utilize whatever vaccines are supplied by donor agencies 
or vendors who have passed through government’s registration processes.
Most countries grapple with unreliable immunization service funding. But in 
spite of active measles vaccination efforts in several developing countries, re-
emergence of measles continues to occur [33]. An interplay of several factors affect 
immunization. These factors include break in cold-chain of measles vaccine due 
to long distance to vaccination centers, history of measles, intercurrent infections 
and malnutrition. In both developing and industrialized countries, loss of public 
confidence in vaccine due to real or spurious links to adverse events can curtail or 
even halt immunization activities. This is similar to reports about polio vaccine 
laced with sterilizing agents which led to decline in vaccination uptake in northern 
Nigeria. Despite the scientific evidence refuting links between the measles-mumps-
rubella (MMR) vaccine and autism, there has been decline in coverage in some 
countries as a result of this. Measles is making a comeback in several industrialized 
countries, including Austria, Italy and the United Kingdom. This can be attributed 
to presence of migrants and refugees from developing countries especially those 
who are biased against vaccines in light spurious or religious sentiments.
Masking of geographical inequalities in vaccination because of poor administra-
tive summaries is a big problem. Spatial clustering of unvaccinated children sus-
tains disease transmission, even when high overall vaccination coverage is achieved. 
Continued measles virus circulation occurs as a result of missing age cohorts during 
routine vaccination. Access to high quality vaccines is important however, there is 
limited expertise to review technical product information in vaccine regulatory dos-
siers hence the inability to effectively register and supply vaccines in many develop-
ing countries. They lack appropriate expertise and certified personnel to perform 
good manufacturing practice (GMP) inspections leading to lengthy registration/
review process and delays in vaccine registration even in emergency situations. 
Worrisome is the fact that there is limited compliance with good clinical practice 
standards for some clinical trials. Therefore, improving vaccine supply chain in 
developing countries is very important. A review of existing data shows freeze 
exposure occurred in 18–67% of vaccine shipments throughout various stages of 
storage. Also, heat denatures vaccines when cold chain is not maintained. Such may 
reduce vaccine potency, ultimately supplying potentially less-effective vaccines.
2.7 Sourcing of vaccines
The developing countries vaccine manufacturers’ network (DCVMN) is a public 
health driven, international alliance of manufacturers trying to strengthen vac-
cine supply through information and professional training programs, technology 
improvements, innovative vaccine research and development, encouraging transfer 
initiatives, to improve availability of safe, effective and affordable vaccines. Three 
goals were proposed for vaccines. First, to ensure uninterrupted supply of afford-
able and suitable vaccines for GAVI. Second, improve market dynamics information 
and expertise to solve vaccine access challenges. Third, strengthening global health 
and manufacturers’ partnerships to enable better alignment of goals, alignment 
with global strategy and coordination of internal investments [43].
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2.8 Negative impact of population explosion
Civil unrest is common in developing countries and this has led to migration of 
millions of people. There is increased movement by land, air and sea. In Northern 
Nigeria, activities of Boko Haram terrorist have caused several families to abandon 
their homelands and converge on Internally Displaced Peoples camps where health 
care services are poor and even non-existent in some cases. Many children are 
born in these camps, but vaccination activities may not be sustained at the desired 
national vaccination level. Wars and famines or other natural disasters increase 
mortality due to measles. In 2000, measles was responsible for 22% of deaths in 
children less than 5 years of age and 17% of deaths in children aged 5–14 years in 
Ethiopia [44]. Increased air travel by people within some regions in developing 
countries has been reported. For local flights, cabin air flow may not be as reliable a 
barrier to the spread of measles virus. Several measles reports, including index cases 
and apparent secondary cases on flights, have been reported in which transmission 
on board the aircraft appeared likely and which included seating information for 
both index (primary) and secondary case [45].
3. Conclusion
Regulations for safety and effectiveness of vaccines in the uncontrolled, real 
world context should be strengthened in developing countries. Perhaps the set of 
ethical considerations when fully operational in developed countries will be applied 
to them also. The World Health Assembly established 3 milestones towards eradi-
cation of measles. They intend to increase routine coverage with MCV1 by more 
than 90% nationally and more than 80% in every district; reduce and maintain 
annual measles incidence to less than 5 cases per million; and reduce estimated 
measles mortality by more than 95%. Based on current trends of measles vaccina-
tion coverage and incidence, and report of the strategic review, the WHO Strategic 
Advisory Group of Experts on Immunization (SAGE) concluded that the 2015 
global milestones and measles elimination goals were not achieved because immuni-
zation coverage gaps exist. SAGE recommended focus on improving immunization 
and surveillance systems to ensure gains made thus far in measles control can be 
sustained. The situation in developing countries requires serious attention and strict 
compliance by stakeholders to ensure goals are met.
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